Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $19.50

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $19.50.

ENTA has been the topic of several research reports. Robert W. Baird dropped their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating on the stock in a report on Tuesday, November 26th. Evercore ISI upgraded Enanta Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, August 6th. JPMorgan Chase & Co. cut their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating for the company in a report on Tuesday, August 6th. JMP Securities reissued a "market outperform" rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th.

Institutional Trading of Enanta Pharmaceuticals

Several hedge funds have recently bought and sold shares of ENTA. Vanguard Group Inc. lifted its position in shares of Enanta Pharmaceuticals by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company's stock valued at $33,664,000 after buying an additional 134,292 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Enanta Pharmaceuticals in the first quarter worth approximately $191,000. Bank of New York Mellon Corp boosted its position in shares of Enanta Pharmaceuticals by 13.3% in the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company's stock worth $958,000 after purchasing an additional 8,645 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter worth $35,000. Finally, Rhumbline Advisers raised its position in shares of Enanta Pharmaceuticals by 4.7% during the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company's stock valued at $448,000 after purchasing an additional 1,548 shares during the period. Institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Stock Down 2.6 %

Shares of NASDAQ ENTA traded down $0.23 during trading on Friday, reaching $8.60. 225,002 shares of the company traded hands, compared to its average volume of 186,321. The firm has a 50 day simple moving average of $10.81 and a 200-day simple moving average of $12.23. Enanta Pharmaceuticals has a 52-week low of $8.00 and a 52-week high of $17.80. The stock has a market capitalization of $182.23 million, a PE ratio of -1.57 and a beta of 0.56.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.